A previous study [73] suggested that high SERPINA1 expressions may predict better clinical outcomes in ER+ and ER+/HER2+ patients, since SERPINA1 is a direct target gene of the estrogen receptor, and its regulation may be mediated by estrogen signaling; thus, this gene may play a protective role in the tumor progression of BC. Here, ERBB2 is linked to neoplasm.